Meningitis moves fast – you must too
-
Over 2.8 million cases of bacterial meningitis occur globally each year3 -
A delay in antibiotic treatment is a strong and independent risk factor for mortality, even after just 6 hours4,5 -
Without treatment, the case-fatality rate for bacterial meningitis can be as high as 70%6 -
28% of community-acquired episodes of bacterial meningitis result in one or more neurologic complications7
Traditional methods alone can’t cut it
-
48 hours
It can take up to 48 hours for pathogen identification using CSF culture1
-
Less than 60%
The sensitivity of Gram stain for bacterial meningitis is only around 60%1
-
20% decrease
The sensitivity of culture and Gram stain may decrease by 20% if antibiotic treatment has occurred1
-
Only 24%
Only 24% of patients with meningitis show abnormal findings with a CT scan2
QIAstat-Dx ME Panel detects 15 common targets that cause CNS infections
References
- Van de Beek D. et al. (2016) Cli Microbiol Infect. 22, S37–S62
- Hasbun R. et al. (2001) N Engl J Med. 345(24), 1727–1733
- GBD 2016 Meningitis Collaborators. (2018) Lancet. 17,1061–1082
- Auburtin M. et al. (2006) Crit Care Med. 34(11), 2758–2765
- Proulx, N., et al. (2005) QJM. 98(4), 291–298
- Rosenstein N.E. et al. (2001) N Engl J Med. 344, 1378–1388
- Durand M.L. et al. (1993) N Engl J Med. 328(1), 21–28
- Cailleaux M. et al. (2019) ) Eur J Clin Microbiol Infect Dis. 39, 293–297
- Moffa M.A., et al. (2020) Antibiotics (Basel). 9(6), 282
- Posnakoglou L. et al. (2020) Eur J Clin Microbiol Infect Dis. 39, 2379–2386
- Leber A. et al. (2016) J Clin Microbiol. 59(4), 2251–2261
The QIAstat-Dx Analyzer is intended for in vitro diagnostic use.
The QIAstat-Dx ME Panel is indicated as an aid in the diagnosis of specific agents that cause meningitis and/or encephalitis, and results must be used in conjunction with other clinical, epidemiological, and laboratory data. Results from the QIAstat-Dx ME Panel are not intended to be used as the sole basis for diagnosis, treatment, or other patient management decisions. Positive results do not rule out co-infection with organisms not included in the QIAstat-Dx ME Panel. The agent or agents detected may not be the definite cause of the disease. Negative results do not preclude central nervous system (CNS) infection.
The QIAstat-Dx ME Panel is intended for in vitro diagnostic use by laboratory professionals only.
Product availability may differ from country to country based on regulations and approvals. Contact your country representative for further details.